List of Excipients in Branded Drug AACETAMINOPHEN AND IBUPROFEN

Generic Drugs Containing AACETAMINOPHEN AND IBUPROFEN

Company	Ingredient	NDC	Excipient
GRANULES USA INC	acetaminophen and ibuprofen	69848-588	CARNAUBA WAX
GRANULES USA INC	acetaminophen and ibuprofen	69848-588	CELLULOSE, MICROCRYSTALLINE
GRANULES USA INC	acetaminophen and ibuprofen	69848-588	CROSCARMELLOSE SODIUM
GRANULES USA INC	acetaminophen and ibuprofen	69848-588	CROSPOVIDONE
GRANULES USA INC	acetaminophen and ibuprofen	69848-588	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in AACETAMINOPHEN AND IBUPROFEN?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE
1	FERRIC OXIDE RED

Acetaminophen and Ibuprofen Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

The acetaminophen and ibuprofen combination is an established over-the-counter analgesic platform with commercial potential in branded generics, private-label products, liquid formulations, softgels, and differentiated rapid-release systems. The main formulation challenge is combining a relatively high acetaminophen load with low-dose, poorly water-soluble ibuprofen while preserving tablet strength, disintegration, dose uniformity, stability, and consumer acceptability.

The leading U.S. reference product is Advil Dual Action, which contains 250 mg ibuprofen and 125 mg acetaminophen per caplet and is marketed by Haleon under an FDA-approved application. The combination is subject to dose limits and warnings for both active ingredients, including gastrointestinal, renal, cardiovascular, hepatic, and overdose risks.[1]

What is the commercial opportunity for acetaminophen and ibuprofen combinations?

The commercial opportunity is concentrated in adult oral analgesics, where consumers seek stronger relief than either ingredient may provide alone without moving to prescription opioids or other prescription therapies.

Product segment	Commercial rationale	Principal development issue
Immediate-release tablets or caplets	Lowest manufacturing cost and broadest retail access	High acetaminophen tablet load and ibuprofen dissolution
Softgels	Premium positioning and rapid consumer-perceived onset	Encapsulation compatibility and higher unit cost
Liquids and suspensions	Pediatric and dysphagia markets	Dose accuracy, taste masking, physical stability
Effervescent products	Rapid dispersion and differentiated user experience	Moisture control, packaging, sodium content
Chewable tablets	Convenience and adherence	Taste, grittiness, ibuprofen irritation
Private-label store brands	Retailer margin and substitution for branded products	Price competition and limited differentiation
Modified-release products	Potential adherence and duration benefits	More complex regulatory and clinical justification

The most defensible near-term opportunity is an immediate-release, low-cost adult product with improved swallowability, reliable disintegration, and a clear label-based positioning around dual-mechanism analgesia. Product claims must remain within the approved labeling and applicable FDA requirements.

How does the fixed-dose combination compare with single-ingredient products?

The combination gives manufacturers a higher-value product than single-ingredient acetaminophen or ibuprofen, but it also carries the safety constraints of both ingredients.

Attribute	Acetaminophen	Ibuprofen	Combination implication
Primary risk	Hepatotoxicity at excessive total daily exposure	Gastrointestinal bleeding, renal injury, cardiovascular risk	Label must communicate both risk profiles
Solubility	Moderately water soluble	Poorly water soluble at low pH	Separate dissolution strategies may be required
Typical consumer positioning	Fever and pain relief	Pain, inflammation, fever	Combination can support broader pain positioning
Tablet burden	Higher dose per unit	Lower dose per unit	Acetaminophen drives tablet mass
Regulatory complexity	Established OTC ingredient	Established OTC ingredient	Fixed-dose combination may require approved NDA or applicable monograph pathway

The combination can reduce reliance on high doses of either component, but the product cannot be marketed as eliminating the risks associated with either active ingredient.

What excipient strategy is appropriate for acetaminophen and ibuprofen tablets?

A direct-compression or dry-granulation formulation is generally the most commercially attractive starting point. Wet granulation may improve content uniformity and mechanical strength but introduces moisture and thermal-processing risks that require stability evaluation.

Recommended excipient functions

Formulation function	Candidate excipient classes	Strategic purpose
Filler or dry binder	Microcrystalline cellulose, dibasic calcium phosphate, pregelatinized starch	Supports tablet size, hardness, and flow
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Accelerates tablet breakup
Wetting or dissolution aid	Poloxamers, surfactants, selected wetting agents	Improves ibuprofen wetting and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force
Binder	Povidone, hydroxypropyl cellulose	Improves granule and tablet strength
Film coating	Hypromellose, polyethylene glycol, titanium dioxide or approved colorants	Improves appearance, swallowability, and odor control
Taste masking	Sweeteners, flavors, polymer coatings	Relevant to chewables and liquids
Suspending system	Xanthan gum, microcrystalline cellulose blends, carbomers	Maintains liquid dose uniformity

The formulation should avoid excessive lubricant levels and prolonged lubrication because both can delay dissolution, particularly when the ibuprofen is already dissolution-limited. Magnesium stearate concentration, blending time, particle size, and surface area require process-control limits.

How should ibuprofen dissolution be improved?

Ibuprofen is the principal biopharmaceutical formulation challenge because it is a weak acid with low aqueous solubility in acidic conditions. Practical options include:

1. Particle-size reduction or micronization.
2. Use of wetting agents or surfactant-containing excipient systems.
3. Amorphous or partially amorphous ibuprofen dispersions.
4. Solid dispersions with hydrophilic polymers.
5. Ibuprofen salts, if the regulatory and stability profile supports the selected salt.
6. Liquid-filled softgels using suitable solvent or cosolvent systems.
7. Separate granulation of ibuprofen before blending with acetaminophen.

The lowest-risk commercial approach is usually micronized or conventionally milled ibuprofen combined with a robust disintegrant and wetting system. Advanced amorphous dispersions may improve dissolution but increase development complexity, moisture sensitivity, and scale-up risk.

How should the acetaminophen load be managed?

Acetaminophen can account for a substantial portion of tablet mass. A high-loading formulation should prioritize:

• High-density, compressible excipients.
• Uniform particle-size distribution.
• Low tablet friability.
• Adequate tensile strength at acceptable compression force.
• Rapid disintegration despite high drug loading.
• Minimal tablet size for consumer acceptability.

Microcrystalline cellulose and pregelatinized starch can provide useful compression properties. Dibasic calcium phosphate may improve density and flow but can alter dissolution behavior and may be less suitable for certain formulation architectures. Excipient selection should be based on powder rheology, compaction profiling, dissolution, and stability rather than on nominal excipient function alone.

What dosage forms are protected by formulation strategy?

The broad active-ingredient combination is difficult to protect with composition-of-matter claims because both APIs are old and widely marketed. Commercial differentiation is more likely to arise from dosage-form, process, delivery, or use claims.

Immediate-release caplets

This is the most direct generic and private-label opportunity. Competitive advantages may include smaller dimensions, easier swallowing, faster disintegration, lower friability, or reduced coating defects.

Softgels

Softgels can differentiate the product through appearance, swallowability, and consumer perception of rapid action. Ibuprofen solubilization is possible in liquid or semisolid fill systems, but acetaminophen incorporation may require suspension technology or a dual-phase design. Gelatin crosslinking, shell moisture, fill compatibility, and oxygen exposure are key development risks.

Oral liquids

A combined liquid is commercially attractive for consumers who cannot swallow tablets, but formulation complexity is high. Ibuprofen requires suspension or solubilization technology, while acetaminophen is more readily incorporated into aqueous systems. The formulation must control sedimentation, redispersibility, viscosity, taste, preservative performance, and dosing-device accuracy.

Pediatric products require separate dose logic and safety positioning. A product designed for adults should not be repurposed for pediatric use without appropriate dosing, labeling, and regulatory support.

Chewables and effervescent products

These forms can support premium pricing but require effective taste masking. Ibuprofen can produce bitterness and irritation, while acetaminophen can contribute a persistent medicinal taste. Effervescent products require moisture-resistant packaging and may introduce sodium or other electrolyte considerations.

What FDA regulatory status applies to acetaminophen and ibuprofen combinations?

Acetaminophen and ibuprofen are established nonprescription active ingredients. A specific fixed-dose combination may require an approved NDA rather than relying solely on the monograph framework, depending on the exact ingredients, strengths, dosage form, labeling, and marketing pathway.

Advil Dual Action is identified in FDA labeling as an acetaminophen and ibuprofen combination product. Its labeled active ingredients are 250 mg ibuprofen and 125 mg acetaminophen per caplet.[1] FDA labeling limits use to adults and children 12 years and older and warns against combining the product with other acetaminophen- or NSAID-containing products.

A developer pursuing an ANDA must establish pharmaceutical equivalence and bioequivalence to the applicable reference product. A product using a different salt, release profile, dosage form, or excipient architecture may require a different regulatory pathway.

What is the Orange Book and patent status of acetaminophen and ibuprofen products?

The Orange Book lists approved drug products and, for applicable NDA products, patent and regulatory-exclusivity information. The relevant reference application for Advil Dual Action should be reviewed directly in the current FDA Orange Book before making a launch, Paragraph IV, or freedom-to-operate decision.[2]

The active ingredients themselves do not provide meaningful new chemical-entity exclusivity. Potential protection may instead involve:

• Fixed-dose ratios.
• Specific tablet or capsule architectures.
• Rapid-release formulations.
• Particle-size specifications.
• Solubilized or amorphous ibuprofen.
• Manufacturing processes.
• Stability improvements.
• Taste-masked liquids or chewables.
• Method-of-use claims covering pain conditions or dosing regimens.

When does the combination lose exclusivity?

There is no single universal expiration date for “acetaminophen and ibuprofen” because exclusivity depends on the particular reference product, application, listed patents, regulatory exclusivity, and jurisdiction. The relevant dates are product-specific and can change with patent-listing corrections, pediatric exclusivity, patent-term adjustments, litigation outcomes, or settlement agreements.

A generic sponsor should separate four questions:

1. Whether the reference product is eligible for an ANDA.
2. Whether the product has listed patents in the Orange Book.
3. Whether those patents remain enforceable or commercially relevant.
4. Whether an ANDA certification creates Paragraph IV litigation risk.

What Paragraph IV challenges and litigation risks exist?

Paragraph IV exposure applies when an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. A notice letter can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework, subject to statutory conditions.[3]

For this combination, the highest-value disputes are likely to concern formulation claims, fixed-dose ratios, release characteristics, and manufacturing limitations rather than API composition claims. A careful diligence review should compare the proposed product against every claim limitation, not merely the ingredient list.

How strong is the patent estate for acetaminophen and ibuprofen?

The underlying API patent estate is weak because acetaminophen and ibuprofen are long-established active ingredients. The formulation estate can still be commercially meaningful where claims require:

• A defined dissolution profile.
• A specified particle-size distribution.
• A particular excipient ratio.
• A multilayer tablet.
• A solubilized ibuprofen phase.
• A stability-enhancing process.
• A defined pharmacokinetic or therapeutic outcome.

Patent strength depends on claim breadth, written-description support, prosecution history, prior-art density, and the ability to design around the limitation. Manufacturing know-how may be more valuable than patent coverage for conventional immediate-release tablets.

Trade-secret protection can cover granulation endpoint, milling parameters, blending sequence, compression settings, coating conditions, and softgel fill processing. These controls may create practical barriers even when patent protection is narrow.

Which companies are competing in this market?

Competition exists across branded, generic, retailer-owned, and international products. Haleon is the principal U.S. branded reference-product sponsor for Advil Dual Action. Generic and private-label manufacturers compete on price, distribution, packaging, dosage form, and retailer relationships.

The market is structurally favorable to large-scale manufacturers because:

• Both APIs are inexpensive.
• Retail substitution is strong.
• Manufacturing technology is mature.
• Retailers can shift volume between national brands and store brands.
• Regulatory compliance and quality systems create more friction than API cost.

A differentiated product needs a measurable benefit such as smaller tablet size, faster disintegration, improved taste, more convenient dosing, or a dosage form not widely available from store brands.

What licensing and partnering opportunities exist?

Licensing opportunities are more likely to involve technology than the active ingredients. Relevant assets include:

• Solubilization platforms for ibuprofen.
• High-load tablet compression systems.
• Taste-masking technology.
• Pediatric suspension systems.
• Softgel or liquid-fill manufacturing capacity.
• Regional OTC registrations.
• Retailer-specific private-label development.

A license should be valued against manufacturing savings, regulatory bridging requirements, patent term, territorial rights, and the ability to use the technology with other NSAID or analgesic combinations. The commercial case is strongest where the technology supports multiple products rather than one conventional tablet.

What generic launch scenarios exist?

Scenario 1: Conventional immediate-release tablet

This is the most likely launch path for a cost-focused entrant. It offers the lowest technical risk but also the weakest differentiation and highest price pressure.

Scenario 2: Paragraph IV launch

A Paragraph IV strategy may create earlier market entry if listed patents are vulnerable or can be designed around. Litigation costs, a potential 30-month stay, and the risk of damages must be included in launch economics.

Scenario 3: Non-infringing differentiated dosage form

A sponsor may avoid key formulation claims through a different excipient system, dosage form, particle-size profile, or manufacturing process. This approach can reduce litigation risk but may require additional development and regulatory work.

Scenario 4: Private-label partnership

A retailer or distributor partnership can provide volume access without the marketing costs of a national brand. Margin pressure is high, and supply reliability is critical.

How should commercial diligence assess the opportunity?

A practical diligence model should measure:

Diligence factor	Key question
Regulatory	Is the proposed product eligible for an ANDA or does it require an NDA?
Patent	Are any listed patents relevant to the proposed formulation or process?
Formulation	Can the product meet dissolution and content-uniformity targets at commercial scale?
Manufacturing	Can existing equipment handle the acetaminophen load and ibuprofen distribution?
Safety	Does labeling clearly control duplicate acetaminophen and NSAID exposure?
Market	Is the product competing on price, convenience, or differentiated performance?
Supply	Are qualified sources available for both APIs and specialty excipients?
Margin	Can the product support retailer discounts, rebates, packaging, and pharmacovigilance costs?

Revenue exposure is most sensitive to retail placement, private-label substitution, manufacturing scale, and any regulatory or litigation delay. API cost is unlikely to determine commercial success.

Key Takeaways

• The acetaminophen and ibuprofen combination is a mature OTC platform with a viable branded-generic and private-label market.
• Acetaminophen drives tablet mass; ibuprofen drives dissolution complexity.
• Direct compression or dry granulation is the most commercially practical starting strategy.
• Micronization, wetting agents, high-performance disintegrants, and controlled lubrication are central formulation tools.
• Softgels, liquids, chewables, and effervescent products offer differentiation but carry higher development and manufacturing risk.
• API composition patents are not a meaningful source of protection; formulation, process, dosage-form, and method-of-use claims are more relevant.
• Orange Book, Paragraph IV, and litigation conclusions must be made at the specific reference-product and jurisdiction level.
• Manufacturing know-how may provide greater practical protection than broad patent coverage.
• The strongest commercial opportunity is a low-cost immediate-release product with a measurable advantage in tablet size, disintegration, swallowability, or retail positioning.

FAQs

Can acetaminophen and ibuprofen be formulated in one tablet?

Yes. A fixed-dose combination can be formulated as an immediate-release tablet or caplet, provided the product meets applicable quality, labeling, safety, and regulatory requirements.

Which excipient improves ibuprofen dissolution the most?

No single excipient is universally optimal. Ibuprofen dissolution commonly improves through particle-size reduction, wetting agents, hydrophilic polymers, solid-dispersion systems, or salt selection.

Is a new acetaminophen and ibuprofen tablet automatically patentable?

No. The old active ingredients do not create new composition-of-matter protection. Patentability usually depends on a novel and non-obvious formulation, process, dosage form, or method of use.

Is a liquid acetaminophen and ibuprofen product commercially attractive?

It can be attractive for dysphagia and pediatric markets, but taste masking, suspension stability, dosing accuracy, and regulatory requirements make it more difficult than a conventional tablet.

Are biosimilar risks relevant to acetaminophen and ibuprofen?

No. These are small-molecule active ingredients, not biologics. Competitive risk arises from generic drugs, private-label products, formulation substitutes, and retailer sourcing rather than biosimilar development.

References

1. U.S. Food and Drug Administration. (2020). Advil Dual Action with acetaminophen: Prescribing information and drug facts labeling. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). ANDA submissions: Refuse-to-receive standards and Paragraph IV certification guidance. FDA.

4. U.S. Food and Drug Administration. (2023). Drug facts labeling requirements for over-the-counter human drugs. FDA.

5. International Council for Harmonisation. (2003). Q8 pharmaceutical development. ICH.

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.